Key Takeaways NVS reported that Cosentyx missed the primary endpoint in a phase III study for giant cell arteritis. Cosentyx plus a 26-week steroid taper showed no significant remission benefit over placebo and 52-week taper. While endpoints were missed, Cosentyx showed lower steroid exposure and consistent safety in the GCA study.Novartis (NVS) announced that a late-stage study of its interleukin-17A inhibitor, Cosentyx (secukinumab), has failed to meet the primary endpoint of sustained remission at week ...

Novartis AG’s blockbuster drug Cosentyx failed in a late-stage trial for treating blood vessel inflammation, a setback to the company’s efforts to broaden its uses https://t.co/3StOAgtgqw ...

这位CEO还强调了公司其他药物获得的新批准，包括前列腺癌治疗药物Pluvicto。 Narasimhan补充道："我们将继续推进领先的研发管线，对实现既定增长目标充满信心。" 此次财报发布之际，全球制药行业正密切关注美国可能加征的关税措施。本月早些时候，特朗普政府宣 布对该行业启动调查。虽然制药产品此前一直免征全面进口关税，但特朗普在三月警告称"很快"将对特 定医药产品征税。 面对潜在的关税压力，欧洲制药企业正加大在美国的投资力度，以期保住这个利润丰厚的市场并优化本 土化生产布局。 展望未来，诺华制药将2025年全年净销售额增长预期从原先的中高个位数上调至高个位数，核心营业利 润增长预期从原先的高个位数至低双位数调整为低双位数。 此次业绩增长主要得益于心衰治疗药物Entresto和关节炎药物Cosentyx这两款畅销药的持续发力。但首 席执行官Vas Narasimhan特别指出，乳腺癌治疗药物Kisqali、多发性硬化症药物Kesimpta以及降胆固醇 药物Leqvio的市场需求正在显著增长。 面对仿制药竞争压力，诺华制药正加速推进创新疗法布局。今年晚些时候，包括Entresto在内的三款核 心药物将面临仿 ...

Ad hoc announcement pursuant to Art. 53 LR Net sales grew +15% (cc1, +12% USD) with core operating income1 up +27% (cc, +23% USD) Sales growth driven by continued strong performance from Entresto (+22% cc), Kisqali (+56% cc), Kesimpta (+43% cc), Cosentyx (+18% cc), Leqvio (+72% cc) and Scemblix (+76% cc) Core operating income margin1 reached 42.1%, +400 basis points (cc), mainly driven by higher net sales Operating income grew +44% (cc, +38% USD); net income up +37% (cc, +34% USD)Core EPS1 grew +31% (cc, ...

Investment Rating - The report assigns an "In-Line" investment rating for the biopharma industry in North America [7] Core Insights - The latest weekly Total Prescription (TRx) year-over-year (YoY) growth for the week ending April 11, 2025, was +2.7%, a decrease from +3.5% the previous week, but consistent with the +2.7% growth over the past 12 weeks [1][2] - The report highlights the launch performance of new drugs, including BMY's Cobenfy for schizophrenia and VRTX's Journavx for acute pain, with specific TRx targets needed to meet consensus sales estimates [3][4] Summary by Sections Market Overview - The US total market weekly TRx YoY change was +2.7% compared to +2.3% a year ago, with a rolling 4-week TRx YoY also at +2.7% [2] - Extended unit (EUTRx) weekly YoY growth was +1.4%, indicating a slower growth rate compared to TRx YoY [2] Drug Launch Analysis - BMY's Cobenfy, approved for schizophrenia, recorded approximately 1,660 scripts for the week, up from 1,580 the previous week, with a target of 105K TRx needed to meet 2025 consensus estimates [3] - VRTX's Journavx, approved for acute pain, had around 2,950 scripts for the week, with an estimated average script size of 35-37 pills, indicating a need for approximately 229K scripts for a 14-day duration to achieve $87 million in sales [4] Prescription Trends - The report includes a detailed analysis of prescription trends for major pharmaceuticals, highlighting significant YoY changes for key products such as Humira, Rinvoq, and Skyrizi [19][21] - The GLP-1 franchise, particularly Mounjaro and Zepbound, showed notable growth, with Mounjaro experiencing a 69% YoY increase [21] Seasonal Vaccine Tracking - The report tracks seasonal respiratory vaccines, noting that RSV vaccine volumes are approximately 65% below last year's levels, while COVID vaccine volumes are also down year-over-year [10]

Core Insights - Oruka Therapeutics is developing ORKA-002, a novel monoclonal antibody with an extended half-life targeting IL-17A/F, which shows potential for less frequent dosing compared to existing therapies [1][3][6] - The half-life of ORKA-002 in non-human primates (NHP) exceeds 30 days, which is over three times longer than bimekizumab, suggesting a dosing interval of two to three times per year [1][6] - ORKA-002 demonstrates equivalent potency to bimekizumab with similar binding affinity, indicating a promising profile for treating chronic skin diseases like plaque psoriasis and psoriatic arthritis [2][3][6] Company Overview - Oruka Therapeutics aims to set a new standard for treating chronic skin diseases, focusing on achieving high rates of complete disease clearance with infrequent dosing [4] - The company is advancing a proprietary portfolio of antibodies engineered to target the core mechanisms of plaque psoriasis and other dermatologic conditions [4] Product Details - ORKA-002 is administered subcutaneously and has shown superior efficacy in preclinical studies compared to existing therapies that require monthly maintenance dosing [3][6] - Projections indicate that ORKA-002 could have a human half-life of approximately 50 to 75 days, allowing for dosing intervals of once every four months or twice a year [6]